Mymetics Acquires Malaria Vaccine From Pevion
Posted on: Tuesday, 20 May 2008, 09:01 CDT
Mymetics, a vaccine development company, has acquired a preventive malaria vaccine from Switzerland-based Pevion Biotech.
The Pevion vaccine has successfully completed human clinical trial Phases I and II in Switzerland and in the UK, respectively, with only two of four contemplated antigens. The clinical trials are being conducted in connection with the application for approval of this vaccine under the EU regulations.
A Phase Ib clinical trial has been launched in Tanzania to extend the protocol to children and teenagers in a naturally endemic area. A new cycle of Phase I and II clinical trials with all four antigens is scheduled thereafter.
Christian Rochet, CEO and president of Mymetics, said: "We are pleased with this acquisition which allows us to start feeding a pipeline of products for the future, in addition to our preventive HIV/AIDS vaccine."
Source: Datamonitor
Related Articles
- Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
- Ichor Melanoma Vaccine Clinical Trial Moves to Highest Dose Level
- Bioject at the Forefront of Product Development With Use of Biojector(R) 2000 in Vical's Expanded DNA Vaccine Clinical Trial
- Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
- Montefiore Medical Center Launches HPV Vaccine Clinic
- VETCO Hospitals, Inc. Announces Start of Anesthesia Free Dentals in Vaccine Clinics
- HHS Secretary Mike Leavitt Attends Flu Vaccine Clinic in Miami
- Are You Rabies-Ready?: Unifour Counties Planning Inexpensive Vaccination Clinics for Pets
- MD-Based Maxim Health Cancels All Flu Vaccine Clinics
- South County Hospital Holds Flu Vaccination Clinics
 |
 |
User Comments (1)
| 1. |
Posted by alix on 05/21/2008, 13:58 that sucks |
RSS Feeds